Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets
Royalty Pharma Deferred Tax Assets and Other Non-Current Assets decreased by 3.1% to $76.85M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 109.4%, from $36.71M to $76.85M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 51.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2024
How to read this metric
An increase generally reflects a growing long-term asset base or deferred tax position, while a decrease suggests asset liquidation or tax benefit utilization.
Detailed definition
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets not classifi...
Peer comparison
Commonly found in the non-current asset section of balance sheets for large, diversified financial firms.
Metric ID:
deferred_tax_assets_other_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.96M | $4.52M | $4.15M | $3.87M | $33.41M | $30.61M | $29.63M | $28.03M | $29.41M | $20.21M | $6.52M | $4.49M | $27.56M | $42.79M | $33.53M | $36.71M | $85.49M | $86.59M | $79.29M | $76.85M |
| QoQ Change | — | -24.2% | -8.2% | -6.6% | +763.4% | -8.4% | -3.2% | -5.4% | +4.9% | -31.3% | -67.7% | -31.2% | +514.0% | +55.3% | -21.6% | +9.5% | +132.9% | +1.3% | -8.4% | -3.1% |
| YoY Change | — | — | — | — | +460.6% | +578.0% | +614.8% | +624.3% | -12.0% | -34.0% | -78.0% | -84.0% | -6.3% | +111.7% | +414.2% | +717.9% | +210.3% | +102.4% | +136.5% | +109.4% |
Range$3.87M – $86.59M
CAGR+71.3%
Avg YoY Growth+241.6%
Median YoY Growth+124.1%
Current Streak2 quarters decline
Deferred Tax Assets and Other Non-Current Assets at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's deferred tax assets and other non-current assets?
- Royalty Pharma (RPRX) reported deferred tax assets and other non-current assets of $76.85M in Q1 2026.
- How has Royalty Pharma's deferred tax assets and other non-current assets changed year-over-year?
- Royalty Pharma's deferred tax assets and other non-current assets increased by 109.4% year-over-year, from $36.71M to $76.85M.
- What is the long-term trend for Royalty Pharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Royalty Pharma's deferred tax assets and other non-current assets has grown at a 51.3% compound annual growth rate (CAGR), from $10.00M to $79.29M.
- What does deferred tax assets and other non-current assets mean?
- The total value of long-term tax assets and other miscellaneous long-term assets.